Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is a significant cause of morbidity, quality-of-life impairment and health-care costs. From a clinical point of view, severe disease can be thought of as AD that is resistant to potent topical corticosteroid or calcineurin inhibitor and UV therapy and that is associated with a considerable effect on quality of life. The European Academy of Dermatology and Venereology Taskforce on AD defined severe disease as a SCORAD severity score of greater than 40. Mycophenolate mofetil (MMF) is an immunosuppressant that blocks the purine biosynthesis pathway of cells via the inhibition of inosine monophosphate dehydrogenase. MMF selectively affects B cells and T cells, as other cells have purine scavenger mechanisms that compensate for this blockage, giving this medication a unique mechanism of action to treat inflammatory disorders. MMF is used in the management of patients with organ transplants, but is now frequently used off-label in the treatment of some autoimmune diseases including AD. Here, we report the clinical and subjective outcomes of each adulthood and childhood refractory atopic dermatitis patients with MMF treatment. The Patients reported clinical improvement and lowering SCORAD, EASI score. There is no adverse events. MMF should be an effective, safe treatment for refractory adult and pediatric AD patients.